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IMPORTANCE Previous studies suggest that depression and anxiety are common in patients
with hidradenitis suppurativa (HS), more so than other dermatological conditions. Yet, to the
authors’ knowledge, no previous systematic review or meta-analysis has estimated the
prevalence or odds ratio (OR) for those psychiatric comorbidities in this population.
OBJECTIVE To assess the prevalence and odds for depression and anxiety in patients with HS.
DATA SOURCES From July 25 to September 30, 2018, observational studies investigating the
prevalence and odds for depression and anxiety in adults with HS were systematically
searched without language restriction from the inception of each database to July 25, 2018,
in PubMed/MEDLINE, Embase, and PsycINFO databases. Searches used various
configurations of the terms hidradenitis suppurativa; acne inversa; depressive disorder;
depression; anxiety; anxiety disorders; phobia, social; suicide; and suicide, attempted. In
addition, the reference lists of included references were screenedmanually.
STUDY SELECTION Two investigators independently screened references that measured
prevalence rates and odds for depressive and anxiety symptoms in patients with HS. Of 136
unique references, 10 ultimately met inclusion criteria.
DATA EXTRACTION AND SYNTHESIS Relevant data were extracted from eligible references.
Authors were contacted to provide further information when necessary. Methodological
quality of included studies was assessed through amodified version of the Newcastle-Ottawa
Scale. Random-effects models were used to synthesize available evidence.
MAIN OUTCOMES ANDMEASURES Prevalence rates and ORs for depression and anxiety in
adults with HS were the primary outcomemeasures. Heterogeneity across studies was
assessed with the I2 statistic. Sources of heterogeneity were explored through subgroup and
meta-regression analyses.
RESULTS Ten studies comprising 40 307 participants with HSmet inclusion criteria. The
overall prevalence of depression was 16.9% (95% CI, 9.9%-27.2%). Heterogeneity was large.
In the subgroup of studies that considered a clinical criteria–based diagnosis of depression,
the prevalence of depression was 11.9% (95% CI, 4.9%-26.2%), compared with 26.8% (95%
CI, 20.4%-34.5%) in studies that used a screening instrument. Themethodological quality of
included studies moderated those findings. The OR for depression in individuals with HS
compared with individuals without HS was 1.84 (95% CI, 1.57-2.15). The prevalence of anxiety
was 4.9% (95% CI, 1.7%-13.2%); there were insufficient data to determine an odds ratio for
anxiety in persons with HS because 2 studies included a comparison group.
CONCLUSIONS AND RELEVANCE This systematic review andmeta-analysis indicates that
depression and anxiety are common comorbid conditions in patients with HS. Results
suggest that the development of strategies to recognize and treat those psychiatric
comorbidities in patients with HS is warranted.
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H idradenitis suppurativa (HS) is a chronic recurrent in-flammatory skin diseasewith a characteristic clinicalpresentationofpainfulandsuppurating lesions inapo-
crine-glandbearing intertriginous regions.1 Theprevalenceof
HS varies between 0.05% to 4.00% depending on the meth-
odology used to estimate the prevalence and the population
studied.2 Hidradenitis suppurativa commonly affects young
populations with a female tomale ratio of 3:1. It is associated
with significant disability,3-5 impairedquality of life,5-7 sexual
dysfunction,8 and disturbed body image.9 Furthermore, pa-
tient perspectives of living with HS convey physical, psycho-
logical, social, and emotional distress.4
Several studies10-15 have assessed the prevalence of psy-
chiatric comorbidities in patientswithHS. Some studies have
indicated an increased prevalence of depression10,16,17 and
anxiety10,11 and an increased risk of suicide in peoplewithHS
comparedwith their healthypeers.11,15However, studies have
used different methodological designs and have included
samples from different settings (eg, clinical vs population-
based samples). Therefore, the exactmagnitude of the preva-
lence and odds of depression and anxiety in patients with HS
is unclear.
Hidradenitis suppurativa is damaging to patient psycho-
socialwell-being anddaily activitieswith an added burden of
stigma and shamewhenHS involves intimate body areas.18,19
It is important to have a proper understanding of the magni-
tudeof theburdenofdepressionandanxiety among individu-
als with HS to determine whether targeted interventions for
these psychiatric disorders in this population are warranted.
In thecurrent systematic reviewandmeta-analysis,weset
out to examine the prevalence and odds for depression and
anxiety in adults with HS. In addition, we aimed to explore
potential sources of heterogeneity across studies.
Methods
Thissystematicreviewandmeta-analysis followedthePreferred
Reporting Items for Systematic Reviews and Meta-analyses
(PRISMA) reporting guideline20 and the Meta-analysis of
Observational Studies in Epidemiology (MOOSE) reporting
guideline (eAppendix in the Supplement).21 The literature
search, title screening, abstract screening, final decision on
eligibilityafter full-textreview,methodologicalqualityappraisal
of included studies, and data extraction were independently
performed by 2 investigators (M.O.M. and A.F.C.).
Search Strategy
From July 15, 2018, to September 30, 2018, we conducted a
systematic search of the PubMed/MEDLINE, Embase, and
PsycINFOelectronicdatabases frominception to July25, 2018.
We used various forms and combinations of the search terms
hidradenitis suppurativa; acne inversa; depressive disorder;
depression; anxiety; anxiety disorders; phobia, social; suicide;
and suicide, attempted. The search strings that were used are
available in theeAppendix intheSupplement.Thissearchstrat-
egywasaugmented throughhandsearching the reference lists
of included references.
Eligibility Criteria
Inclusion and exclusion criteria were specified before the lit-
erature search was initiated. No restrictions were made as to
publicationdate or language.Observational studies of anyde-
sign were considered for inclusion. We included studies in
which participants with HS were diagnosed by a physician.
In addition, studies had to provide either the prevalence or
theassociation (whena referencecomparisongroupwasavail-
able) of depression or anxiety. Specifically, we included stud-
ies that provided either Diagnostic and Statistical Manual of
Mental Disorders fifth edition (DSM-5)22 or International
Classification of Diseases, TenthRevision (ICD-10)23 diagnoses
of adepressivedisorder or ananxietydisorder. In addition,we
includedstudies inwhichavalidatedscreening toolwithacut-
off score indicated the possible occurrence of depression or
anxiety as well as studies that used validated algorithms to
detect the possible presence of those mental health condi-
tions. There were no limitations regarding the comparison
group instudies thatassessedtheodds fordepressionandanxi-
ety inadultswithHS.Whenmore than1comparisongroupwas
provided,we prioritized a healthy control group. Studies that
enrolledpediatricpatients (ie,withparticipantsaged<18years)
were excluded.
Data Extraction
Weextracteddata regarding theprevalenceor oddsof depres-
sionandanxiety fromeligible studies.WhenORswerenotpro-
vided, we calculated this metric based on raw data provided
by the included studies. In addition, the following variables
were also extracted when available: (1) sample size; (2) mean
age; (3) sex (% female); (4) measure of severity for HS;
(5) method used to assess depression or anxiety (ie, struc-
tured diagnostic interview or coded diagnosis given by clini-
cian or screening tool or validated algorithm); (6) study de-
sign; and (7) setting (eg, outpatient services or population-
based sample). Both crude and adjusted association metrics
with 95% CIs were extracted from included studies. When a
studydidnotprovideextractable information, thecorrespond-
ing authorwas contacted in at least 2 different occasions over
a period of 2 weeks to obtain the relevant primary epidemio-
logic data.
Key Points
Question What are the prevalence rates of and odds for
depression and anxiety in adults with hidradenitis suppurativa?
Findings This systematic review andmeta-analysis of 10 studies
comprising 40 307 participants with hidradenitis suppurativa
found a prevalence of depression of 16.9% and a prevalence of
anxiety of 4.9%. The odds ratio for depression among people with
hidradenitis suppurativa was 1.84.
Meaning Depression and anxiety are common comorbidities in
people with hidradenitis suppurativa; efforts toward recognition,
prevention, andmanagement of those psychiatric comorbidities
are warranted.
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Methodological Quality Appraisal
TheNewcastle-OttawaScale (NOS)wasused to rate themeth-
odological quality of included studies. Because the NOS was
primarilydesignedtoassess themethodologicalqualityofcase-
control or cohort studies, we used an adapted version to rate
the methodological quality of cross-sectional studies.24,25
Higher scores in the NOS indicate better methodological
quality.25
Statistical Analysis
The prevalence rates or unadjusted ORs and 95% CIs ob-
tained or calculated from included studies were synthesized
by random-effects models when at least 3 independent data-
sets were available for each prevalence or association mea-
sure. Heterogeneity across studies was measured with the I2
statistic; values greater than 50% are indicative of greater
heterogeneity.26 When at least 10 studies were available, we
estimated the likelihood of publication bias using the Egger
asymmetry test.27,28Weused the followingassumptions toas-
sess the existence of small-study effect, an indication of pub-
licationbias: (1) the effect size of the largest study ismore con-
servative thantheeffect sizeof themeta-analysisand(2)P < .10
in theEgger test.29The trim-and-fill procedurewasused toes-
timate the effect size when publication bias was noted.30
We explored potential sources of heterogeneity across
studies using either subgroup (when at least 3 independent
datasets were available per subgroup) or unrestricted maxi-
mumlikelihoodrandom-effectsmeta-regressionanalyses.The
method used to assess depression and anxiety and the study
setting were considered in subgroup analyses. Meta-
regressionanalyseswereconductedonlywhenthereweredata
frommore than 5 independent datasets. Formeta-regression
analyses,we considered the followingvariables: (1)meanage;
(2) percentage of female participants; (3) severity of HS as de-
terminedbyphysician; and (4)methodologicalquality (ie,NOS
score). In addition, sensitivity analyses in which 1 study was
excluded from analysis at a time were conducted for studies
that assessed the odds for depression in adults with HS.
The statistical significance level for effect size estimates
was set at a 2-tailed α of.05. All statistical analyses were con-
ducted in Comprehensive Meta-Analysis Software version 3
(Biostat).
Results
Study Selection
Our literature search and study selection process are de-
picted inFigure 1. The initial searchof databases retrieved 137
references. After 1 duplicate record was removed, 136 refer-
ences were screened on the basis of title, abstract, or both to
determine potential eligibility. Ten unique referencesmet in-
clusion criteria.10-12,14,16,17,31-34 No additional references were
identified from the bibliographies of included articles.
Hidradenitis Suppurativa and Depression
Ten studies assessed the prevalence of depression in patients
with HS (Table 1 and Figure 2A). The median (interquartile
range [IQR])modifiedNOS score of those studieswas4.5 (3.0-
7.0). The overall prevalence of depressionwas 16.9% (95%CI,
9.9%-27.2%). There was no evidence of publication bias
(Egger test, P = .22; eFigure 1 in the Supplement). Hetero-
geneitywasgreat (I2 = 99.4%). In subgroupanalysis, thepreva-
lencewas11.9%(95%CI,4.9%-26.2%;κ = 4; I2 = 99.7%) instud-
ies that considered a clinical criteria–based diagnosis of
depression; whereas in studies that used a screening instru-
ment, the prevalence of probable depression as determined
by the instrument was 26.8% (95% CI, 20.4%-34.5%; κ = 5;
I2 = 73.8%). Theprevalence of depressionwas 25.9% (95%CI,
22.7%-29.4%; κ = 7; I2 = 61.9%) among outpatients with HS.
The methodological quality of included studies did not ap-
pear to moderate the prevalence of depression in HS (coeffi-
cient of variation = 0.06; z = 0.34; κ = 10; P = .73). In addi-
tion, the percentage of female patients (coefficient of
variation = 0.00; z = 0.16; κ = 8; P = .87) andmean age (coef-
ficient of variation = –0.20; z = –1.89; κ = 8; P = .06) did not
moderate the prevalence of depression in HS. The pooled OR
fordepressionwas 1.84 (95%CI, 1.57-2.15; κ = 5) in studies that
included a comparison group (Table 2 and Figure 2B). In sen-
sitivity analyses where 1 studywas excluded from analysis at
a time, the OR for depression in HS remained significant
(eFigure 2 in the Supplement).
Hidradenitis Suppurativa and Anxiety
Fourstudiesmeasuredtheprevalenceofanxiety inpatientswith
HS (Table 1andFigure3).Themedian (IQR)modifiedNOSscore
of included studies was 6.6 (5.5-7.7). The prevalence of anxi-
etywas4.9% (95%CI, 1.7%-13.2%).Heterogeneity across stud-
ies was high (I2 = 99.1%). Of the 4 studies, 2 included a com-
parison group (Table 2). The unadjusted ORs for those studies
were 1.6 and2.3,whereas theORsof both studieswere 1.7 after
multivariable adjustment for potential confounding variables.
Figure 1. Flowchart of Study Selection
137 Records identified through database searching
136 Records after duplicates removed
136 Records screened
34 Full-text articles assessed for eligibility
10 Studies included in qualitative and quantitative
syntheses
24 Full-text articles excluded
11 Duplicate
1 Depressive symptoms (no cutoff)
4 No data available
4 Not an original article
2 Not depression or anxiety 
2 Intervention study
102 Records excluded
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Discussion
Toourknowledge, this is the first systematic reviewandmeta-
analysis to assess theprevalence and relative odds for depres-
sion and anxiety in adults with HS. Our results indicate that
both comorbidities are common among adults with HS, al-
though fewer studies assessed anxiety in this population, and
hence evidence remains preliminary. In addition, the preva-
lence of depressionwas higher among patients with HS com-
paredwith the respectivecomparisongroupsof includedstud-
ies.Twostudiescomparedtheprevalenceofanxiety inpatients
withHS tohealthycontrols,10,11 and thusameta-analysis could
not be conducted.
Our results highlight that efforts toward the recognition
and management of depression among patients with HS are
warranted. Furthermore, the consequences of depression
and anxiety on HS-related outcomes have recently received
more attention. For example, those psychological distress
symptoms may be independently associated with health-
related quality of life in patients with HS.6,34 In addition,
impaired body image in patients with HS was associated
with symptoms of both depression and anxiety in a previous
study, suggesting that the association between depression
and the manifestations of HS may not be independent.9
Therefore, clinical correlates of depression and anxiety
among people with HS as well as the interaction of those
psychiatric comorbidities with HS merit further investiga-
tion. Our exploratory meta-regression analysis did not pro-
vide evidence that sex and age moderate the prevalence of
depression among adults with HS. However, this is a topic
that merits further investigation.
Table 1. Characteristics of StudiesMeasuring the Prevalence of Depression and Anxiety in PeopleWith HS
Source Country
Study
Design
Mean
Age,
y
Female,
%
Sample
Size,
No. Setting
Severity
Assess-
ment
Severe
HS
(%)
Diagnosis
HS
Diagnosis
MDD
Preva-
lence, %
(95% CI)
P
Value
NOS
Score
Depression
Ingram
et al,162018
United
Kingdom
Cross-
sectional
study
43.2 74.3 24 027 Outpatient NA NA Physician
diagnosis
ICD-10 25.5
(25.00-
26.10)
<.001 5
Thorlacius
et al,11 2018
Denmark Prospective
cohort
study
45.8 73.6 7732 Population-
based study
Hurley
staging
system
NA ICD-10 ICD-10 1.6
(1.4-1.9)
<.001 7
Huilaja
et al,14 2017
Finland Retro-
spective
study
39.6 58.7 4381 Inpatient/
outpatient
NA NA Physician
diagnosis
ICD-10 15.1
(14.1-16.2)
<.001 8
Shavitet
al,102015
Israel Cross-
sectional
study
39.6 61.6 3207 Inpatient/
outpatient
NA NA Physician
diagnosis
Clinical
diagnosis
5.9
(5.1-6.8)
<.001 7
Vangipuram
et al,31 2016
United
States
Retro-
spective
study
NA 81.3 283 Outpatient Hurley
staging
system
18.7 Physician
diagnosis
ICD-10 24.4
(19.7-29.7)
<.001 3
Rayner
et al,33 2015
United
Kingdom
Cross-
sectional
study
NA NA 213 Outpatient NA NA Physician
diagnosis
PHQ-9
≥10
23.0
(17.8-29.1)
<.001 5
Onderdijk
et al,12 2013
The
Netherlands
Cross-
sectional
study
43.0 77.0 211 Outpatient Hurley
staging
system
13.5 Physician
diagnosis
MDI ≥20 20.9
(15.9-26.9)
<.001 5
Kirby
et al,342017
United
States/
Denmark
Cross-
sectional
study
40.9 84.4 154 Outpatient NA NA Physician
diagnosis
HADS ≥11 35.7
(28.5-43.6)
<.001 3
Matusiak
et al,32 2010
Poland Cross-
sectional
study
39.9 51.8 54 Outpatient Hurley
stage
system
22.2 Physician
diagnosis
BDI-SF
≥10
20.4
(11.7-33.2)
.11 3
Kurek et al,17
2013
Germany Cross-
sectional
study
34.3 54.5 45 Outpatient Sartorius
score
NA Physician
diagnosis
HADS ≥8 37.8
(24.9-52.6)
<.001 4
Anxiety
Thorlacius
et al,11 2018
Denmark Prospective
cohort
study
45.8 73.6 7732 Population-
based study
Hurley
staging
system
NA ICD-10 ICD-10 0.8
(0.6-1.1)
<.001 7
Huilaja
et al,14 2017
Finland Retro-
spective
study
39.6 58.7 4381 Population-
based study
NA NA Physician
diagnosis
ICD-10 6.9
(6.2-7.7)
<.001 8
Shavit et al,10
2015
Israel Cross-
sectional
study
39.6 61.6 3207 Inpatient/
outpatient
NA NA Physician
diagnosis
Clinical
diagnosis
3.9
(3.3-4.6)
<.001 7
Rayner
et al,33 2015
United
Kingdom
Cross-
sectional
study
NA NA 213 Outpatient NA NA Physician
diagnosis
PHQ-9
≥10
22.5
(17.4-28.6)
<.001 5
Abbreviations: BDI-SF, Beck Depression Inventory Short Form; HADS, Hospital Anxiety and Depression Scale; HS, hidradenitis suppurativa; ICD-10, International
Classification of Diseases, Tenth Revision; MDD, major depressive disorder; MDI, Major Depression Inventory; NA, not available; NOS, Newcastle-Ottawa Scale;
PHQ-9, Patient Health Questionnaire 9.
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Although our findings indicate that depression and anxi-
etymay be common among people with HS, whether there is
acausal relationship inthoseassociationsremains tobeproved.
For example, obesity and related metabolic disturbances are
common in bothHS35 anddepression,36 andmay thus at least
partly explain the associations herein reported. On the other
hand, common pathophysiological mechanisms may under-
pin these associations. For instance, peripheral immune
Table 2. Odds for the Occurrence of Depression and Anxiety in Studies That Included a Healthy Control Comparison Group
Source Country
Sample
Size HS
Sample Size
Control Group Setting Diagnosis
OR (95% CI)
NOS
ScoreNot Adjusted Adjusted
Depression
Ingram et al,16 2018 United Kingdom 24 027 93 869a Outpatient ICD-10 1.69 (1.62-1.77) NA 5
Thorlacius et al,11 2018 Denmark 7732 4 354 137b Population
based study
ICD-10 2.04 (1.71-2.43) 1.13 (0.87-1.47)c 7
Shavit et al,10 2015 Israel 3207 6412d Inpatient and
outpatient
ICD-10 1.71 (1.40-2.08) 1.7 (1.4-2.1)e 7
Onderdijk et al,12 2013 The Netherlands 211 230f Outpatient MDI ≥20 2.06 (1.22-3.48) NA 5
Kurek et al,17 2013 Germany 45 41g Outpatient HADS ≥8 24.28 (3.05-193.24) NA 4
Anxiety
Thorlacius et al,11 2018 Denmark 7732 4 354 137b Population
based study
ICD-10 2.61 (2.04-3.34) 1.73 (1.23-2.41)c 7
Shavit et al,10 2015 Israel 3207 6412g Population-
based study
ICD-10 1.6 (1.3-2.1) 1.7 (1.3-2.1)e 7
Abbreviations: HADS, Hospital Anxiety and Depression Scale; HS, hidradenitis
suppurativa; ICD-10, International Classification of Diseases, Tenth Revision;
MDI, Major Depression Inventory; NA, not available; NOS, Newcastle-Ottawa
Scale; OR, odds ratio.
a Primary care attendees without HS.
bGeneral population controls.
c Adjusted for age, sex, socioeconomic status, smoking, alcohol abuse, and
health care consumption.
d Patients without HS.
e Adjusted for age and sex.
f Patients with other diseases matched for age and sex to the HS sample.
g Healthy controls selected from the general populationmatched to the HS
sample for age, sex, and bodymass index.
Figure 2. Prevalence of Depression in PatientsWith Hidradenitis Suppurativa (HS)
–0.5 0.5 1.00
Event Rate (95% CI)
P ValueSource Event Rate (95% CI)
<.001Total 0.17 (0.10-0.27)
<.001Ingram et al,16 2018 0.25 (0.25-0.26)
<.001Thorlacius et al,11 2018 0.02 (0.01-0.02)
<.001Huilaja et al,14 2017 0.15 (0.14-0.16)
<.001Shavit et al,10 2015 0.06 (0.05-0.07)
<.001Vangipuram et al,31 2016 0.24 (0.20-0.30)
<.001Rayner et al,33 2015 0.23 (0.18-0.29)
<.001Onderdijk et al,12 2013 0.21 (0.16-0.27)
<.001Kirby et al,34 2017 0.36 (0.28-0.44)
<.001Matusiak et al,32 2010 0.20 (0.12-0.33)
.11Kurek et al,17 2013 0.38 (0.25-0.53)
P ValueSource Odds Ratio (95% CI)
<.001Total 1.84 (1.57-2.15)
<.001Ingram et al,16 2018 1.69 (1.62-1.77)
<.001Thorlacius et al,11 2018 2.04 (1.71-2.44)
<.001Shavit et al,10 2015 1.71 (1.40-2.08)
.01Onderdijk et al,12 2013 2.06 (1.22-3.48)
<.001Kurek et al,17 2013 24.28 (3.05-193.24)
0.1 100101
Odds Ratio (95% CI)
Prevalence of depressionA
Depression with HS vs healthy controlsB
Less
Prevalent
More
Prevalent
Less
Prevalent
More
Prevalent
A, Prevalence of depression.
B, Association of depression with HS
vs healthy control participants.
Associations are reported as odds
ratios. Sizes of squares are
proportional to sample sizes.
Squares indicate individual studies;
diamonds, pooled effect sizes.
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activation may contribute to the development of depression
inameaningful subsetofpatients.37,38Accordingly, it hasbeen
recently hypothesized that peripheral inflammation
may contribute to the frequent occurrence of depressive
symptoms inpatientswith inflammatory skindiseases includ-
ing HS.18 Future prospective studies are thus needed to
determine whether there is a causal relationship between
these disorders.
Limitations
Some limitations of the current systematic review andmeta-
analysis merit discussion. First, to our knowledge, no study
has assessed the presence of depression or anxiety among
people with HS through validated structured diagnostic in-
terviews,which are the criterion standard for the assessment
of those disorders. Our subgroup analysis suggests that the
prevalence of depression was greater in studies that used
screening instruments (ie, 26.8%) compared with those that
consideredaclinical criteria–baseddiagnosisofdepression (ie,
11.9%). Thus, the prevalence of depression and anxiety could
have been overestimated to a certain extent, owing to differ-
ences in themethods used to assess thosemental health con-
ditions across studies. Second, themethodological quality of
included studies varied. Third, althoughwe observed greater
odds fordepressionamongadultswithHS, comparisongroups
havevariedacross studies. In addition, the largest population-
basedstudyconducted todate found thatnotwithstanding the
odds for depression were higher in adults with HS, those dif-
ferencesdisappearedafter adjustment forpotential confound-
ing variables.11 It should also be noted that only 2 of the in-
cluded studies10,11 provided adjusted association metrics for
depression inadultswithHS;hence, further large-scale studies
considering potential confounding variables arewarranted to
confirmour findings.Finally,heterogeneityacross studieswas
great. Owing to the relatively few studies available, we could
only explorepotential sources of heterogeneity in studies that
assessed the prevalence of depression in people with HS.
Conclusions
This systematic review and meta-analysis indicates that de-
pression and anxiety are common in patients with HS, al-
though the evidence base for anxiety was more limited than
that for depression. In addition, although our results suggest
that theoddsof depression couldbe greater in adultswithHS,
substantial limitations in the available literature diminish the
certainty of those findings. Therefore, research efforts should
be directed to further elucidate potential moderators as well
as those associations that may indicate a causal relationship.
Inaddition, efforts shouldbedirected to recognizingand treat-
ing those psychiatric comorbidities in patientswithHS to im-
prove health outcomes. Finally, strategies for the manage-
ment of depression and anxiety in adultswithHS are relevant
research directions opened by the current work.
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